Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
US2016115205A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016115205-A1 |
| Application number | US-201414784496-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 15, 2014 |
| Priority date | Apr 15, 2013 |
| Publication date | Apr 28, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1) particular, to a polyvalent vaccine for HIV-1 and to methods of making and using same.
Opening claim text (preview).
What is claimed is: 1 . A composition comprising an HIV-1 envelope AA104.0 ( FIG. 6 , SEQ ID NO: 1), AA107.0 ( FIG. 6 , SEQ ID NO: 2), AA058.1 ( FIG. 6 , SEQ ID NO:3), or a combination thereof. 2 . The composition of claim 1 comprising AA104.0 (SEQ ID NO: 1), AA107.0 (SEQ ID NO: 2) and AA058.1(SEQ ID NO:3). 3 . The composition of claim 1 or 2 , wherein the envelope is a gp120Delta N-terminus polypeptide from SEQ ID NOs: 1, 2 or 3. 4 . The composition of any one of claims 1 - 3 , further comprising HIV-1 envelope B.6240 gp120D11 and A244 gp120 D11. 5 . A composition comprising the gp120Delta N-terminus polypeptide from AA104.0 ( FIG. 6 , SEQ ID NO: 1), AA107.0 ( FIG. 6 , SEQ ID NO: 2), AA058.1 ( FIG. 6 , SEQ ID NO: 3), B.6240 gp120D11 and A244 gp120 D11. 6 . The composition of any one of claims 1 - 5 , wherein the envelope is a recombinant protein. 7 . A composition comprising a nucleic acid encoding any one of envelopes of AA104.0 ( FIG. 6 , SEQ ID NO: 1), AA107.0 ( FIG. 6 , SEQ ID NO: 2), AA058.1 ( FIG. 6 , SEQ ID NO: 3), or the gp120Delta N-terminus polypeptide therefrom. 8 . The composition of claims 1 - 5 further comprising an adjuvant. 9 . The composition of claim 8 , wherein the adjuvant is a Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion (GLA/SE). 10 . A method of inducing an immune response in a subject comprising administering to the subject the composition of any one of claim 1 or 5 in an amount sufficient to effect the induction. 11 . The method of claim 10 wherein the composition is administered as a boost.
for HIV · CPC title
Multivalent vaccine · CPC title
Viral antigens · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
from viruses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.